Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1FED 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 290Prostatic Neoplasms 192Neoplasm Metastasis 154Multiple Myeloma 147Colorectal Neoplasms 123Lung Neoplasms 104Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 88Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 80Stomach Neoplasms 76Small Cell Lung Carcinoma 72Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 66Pain 66Uterine Cervical Neoplasms 64Carcinoma, Renal Cell 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

Glycoprotein Hormones, alpha Subunit 1Chorionic Gonadotropin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Anovulation × Clear all
NCT01653743 2016-01-07

Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women

Merck KGaA, Darmstadt, Germany

Phase 3 Completed
81 enrolled 11 charts

Anovulation, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡